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We characterized five different vaccine candidates and a commercial vaccine in terms
of safety, immunogenicity and using a systems vaccinology approach, with the aim to
select novel vaccine candidates against Mycoplasma hyopneumoniae. Seven groups of
sixM. hyopneumoniae-free piglets were primo- and booster vaccinated with the different
experimental bacterin formulations, the commercial vaccine Hyogen® as a positive
control or PBS as a negative control. The experimental bacterin was formulated with
cationic liposomes+ c-di-AMP (Lipo_AMP), cationic liposomes+ Toll-like receptor (TLR)
2/1, TLR7, and TLR9 ligands (TLR ligands; Lipo_TLR), micro-particles + TLR ligands
(PLGA_TLR), squalene-in-water emulsion + TLR ligands (SWE_TLR), or DDA:TDB
liposomes (Lipo_DDA:TDB). Lipo_DDA:TDB and Lipo_AMP were the most potent in
terms of serum antibody induction, and Lipo_DDA:TDB, Lipo_AMP, and SWE_TLR
significantly induced Th1 cytokine-secreting T-cells. Only PLGA_TLR appeared to induce
Th17 cells, but was unable to induce serum antibodies. The transcriptomic analyses
demonstrated that the induction of inflammatory and myeloid cell blood transcriptional
modules (BTM) in the first 24 h after vaccination correlated well with serum antibodies,
while negative correlations with the same modules were found 7 days post-vaccination.
Furthermore, many cell cycle and T-cell BTM upregulated at day seven correlated
positively with adaptive immune responses. When comparing the delivery of the identical
TLR ligands with the three formulations, we found SWE_TLR to be more potent in the
induction of an early innate immune response, while the liposomal formulation more
strongly promoted late cell cycle and T-cell BTM. For the PLGA formulation we found
signs of a delayed and weak perturbation of these BTM. Lipo_AMP was found to
be the most potent vaccine at inducing a BTM profile similar to that correlating with
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adaptive immune response in this and other studies. Taken together, we identified
four promising vaccine candidates able to induce M. hyopneumoniae-specific antibody
and T-cell responses. In addition, we have adapted a systems vaccinology approach
developed for human to pigs and demonstrated its capacity in identifying early immune
signatures in the blood relating to adaptive immune responses. This approach represents
an important step in a more rational design of efficacious vaccines for pigs.
Keywords: Mycoplasma hyopneumoniae, bacterins, safety, immune responses, transcriptomics
INTRODUCTION
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary
cause of enzootic pneumonia (EP), a chronic respiratory disease
in pigs. The disease causes severe economic losses in swine-
producing countries worldwide due to a reduced average daily
weight gain of the pigs, a higher feed conversion ratio and
an increased use of antimicrobial agents (1–3). Control of the
disease can be achieved by optimizing management and housing
conditions combined with medication and vaccination (2).
Vaccination with inactivated, adjuvanted whole-cell bacterins
is practiced worldwide to control EP (4). However, current
commercial vaccines only offer partial protection, have a limited
effect on the transmission of the microorganism and cannot
prevent colonization (5–7). Most commercial bacterins are based
on the J-strain, a low virulent M. hyopneumoniae strain isolated
in the UK in the sixties (8–10), and contain adjuvants including
aluminum hydroxide, carbopol, mineral oil or biodegradable oil
(4). The main effects of vaccination are a reduction in clinical
symptoms, lung lesions, medication use, and performance
losses (11, 12). Those effects may vary between pig herds (2),
which could be partially explained by antigenic and pathogenic
differences between the strains circulating in the herd and the
vaccine strain (10).
The immune mechanisms leading to protection against
M. hyopneumoniae infection are complex and not yet fully
elucidated. M. hyopneumoniae-specific serum antibody
concentrations induced by vaccination are not correlated
with the severity of lung lesions in M. hyopneumoniae-infected
pigs (5, 13), indicating that systemic antibodies play only a minor
role in protective immunity. However, local mucosal antibodies
(IgA) are considered important to prevent and control M.
hyopneumoniae-induced pneumonia, as the adherence of the
microorganism to the ciliated epithelium of the respiratory tract
is the first step in the pathogenesis (14). Also, several studies
suggest that systemic cell-mediated immune responses play a
major role in disease protection (14–17).
Abbreviations: EP, enzootic pneumonia; CCU, color changing units; PLGA,
poly(lactic-co-glycolic acid); SWE, squalene-in-water emulsion; DDA,
dimethyl dioctadecylammonium; DPPC:DC-Chol, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine and dimethylaminoethane carbamoyl cholesterol; TDB, trehalose
6,6-dibehenate; c-di-AMP, cyclic diadenylate monophosphate; PAM, Pam3Cys-
SK4; CpG, CpG ODN SL03; PS, particle size; Pdi, polydispersity index; ZP, zeta
potential; IM, intramuscularly; ID, intradermally; ISR, injection site reaction;
ADG, average daily gain; BAL, bronchoalveolar lavage; GSEA, gene set enrichment
analysis; FDR, false discovery rate; DEG, differentially expressed genes; BTM,
blood transcriptional modules.
Based on this knowledge, innovative bacterin formulations
that include virulent M. hyopneumoniae strains formulated with
adjuvants specifically designed to promote cellular immune
responses could improve vaccine efficacy. Therefore, we
developed three different vaccine formulations to deliver a
cocktail of TLR 2/1, TLR 7, and TLR 9 ligands previously shown
to potently activate porcine antigen presenting cells including
dendritic cells (DC), monocytes and B cells (18, 19). The
formulations included a liposomal, a micro-particle and an oil-
in-water formulation. In addition, we developed a liposomal
formulation to deliver a cyclic di-nucleotide targeting the STING
pathway (20) as an alternative immunostimulant, and another
cationic liposomal formulation to deliver a Mincle ligand, also
previously found to be efficacious (21). All formulations were
based on the M. hyopneumoniae strain F7.2C, a highly virulent
field strain isolated in Belgium in 2000 (22, 23), and shown to be
antigenically different from the J-strain (23).
Overall, the aim of this study was to assess the safety of
these five novel bacterin formulations and characterize the
immune responses induced by the formulations, compared to
a commercial vaccine in order to select new promising vaccine
candidates. To this end, M. hyopneumoniae-specific T cell
responses and antibody responses were measured in pigs. For T
cells, we focussed on Th1 and Th17 based on their known role in
protective immunity against Mycoplasma infection, as identified
in mouse models (24). Next to that, we employed a systems
immunology approach to understand how different formulations
modulate the immune system toward potent immunogenicity.
This analysis employed “blood transcriptional modules” (BTM)
defined for peripheral blood cells in human (25), which were
adapted to pigs. This technique sheds light into the black
box of the immune response by identifying pathways and
networks of genes related to adaptive immune responses as
previously demonstrated for human and sheep (25–34). Also, this
approach has been shown to possess more discriminative power
for analyses of peripheral blood leukocytes during vaccination
when compared to gene sets based on canonical pathways (25).
Our work has demonstrated the possibilities of such novel
approaches in vaccinology and identified vaccine candidates for
further exploration.
MATERIALS AND METHODS
Vaccines
The vaccine strain M. hyopneumoniae F7.2C was grown in
modified Friis medium (35) for 5 days at 37◦C. The culture,
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containing 5 × 108 color changing units (CCU)/ml, was
inactivated by incubation with 4mM binary ethyleneimine (BEI)
under agitation at 37◦C for 24 h. Subsequently, the BEI was
neutralized by incubating the inactivated culture with 4mM
sodium thiosulfate under agitation at 37◦C for 24 h. Inactivated
bacteria were pelleted at 15,000 g for 40min at 4◦C and washed
three times in 50ml sterile phosphate buffered saline (PBS). The
final pellet was resuspended in sterile PBS.
For this study, five adjuvant formulations were developed
based on the association of particle-based delivery systems
[liposomes, poly(lactic-co-glycolic acid) [PLGA] microparticles
and a squalene-in-water emulsion (SWE)] with different
immune stimulators. These included the Mincle agonist
trehalose 6,6-dibehenate (TDB, Avanti, Alabaster, AL, USA), the
STING ligand cyclic diadenylate monophosphate (c-di-AMP,
produced at the Helmholtz Center for Infection Research,
Braunschweig, Germany) and a combination of TLR ligands:
TLR1/2 ligand Pam3Cys-SK4 (PAM, EMC Microcollections,
Tübingen, Germany), TLR9 ligand CpG ODN SL03 (CpG,
Eurofins Genomics, Les Ulis, France), and TLR7/8 ligand
resiquimod (Chemdea, Ridgewood, NJ, USA).
Two cationic liposome formulations were produced, based
on the thin lipid film method (36), and followed by extrusion:
TDB was combined with dimethyl dioctadecylammonium
(DDA) bromide to form Lipo_DDA:TDB, and c-di-AMP was
encapsulated into 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
and dimethylaminoethane-carbamoyl-cholesterol (DPPC:DC-
Chol) cationic liposomes (37) to obtain Lipo_AMP. The TLR
ligand selection was combined in different delivery systems:
PLGA micro-particles, cationic liposomes and SWE. Cationic
liposomes (DPPC:DC-Chol) and PLGA cationic micro-particles
(combined to ethylaminoethyl-dextran) were produced with the
thin lipid film and the double emulsion (W/O/W) methods (38),
respectively. Pam3Cys-SK4 and resiquimod were encapsulated
into both types of particles and CpG was later adsorbed to their
surface to form the Lipo_TLR and PLGA_TLR formulations.
Finally, for the SWE_TLR formulation, SWE [a squalene-
based formulation developed and produced by the Vaccine
Formulation Laboratory, and composed of 3.9% (w/v) squalene,
0.5% (w/v) Tween 80 and 0.5% (w/v) Span 85 (39)] was mixed
with the same immune stimulators (PAM, CpG, and resiquimod).
For each formulation we measured the following physico-
chemical characteristics: particle size (PS), polydispersity index
(Pdi), and zeta potential (ZP), by means of dynamic light
scattering for the liposomes and SWE, and laser diffraction
for the micro-particles (Zetasizer Nano ZS and Mastersizer
3000, Malvern, UK). The amounts of immune-stimulators
loaded into the Lipo_AMP and Lipo_TLR formulations were
indirectly determined by the use of nanodrop (for c-di-
AMP) and fluorescently labeled immune-stimulator (CpG-
FITC and Pam-Rodhamine, Invivogen, San Diego, CA, USA)
methods. The free immune-stimulators were separated from
the liposomes by filtration using the Vivaspin R© 500 centrifugal
concentrator (PED membrane, MWCO 100 kDa, Sartorius,
Göttingen, Germany) and then quantified as mentioned
above (Supplementary Table 1) Antigenwasmixedwith the final
product, and PS and ZP of the formulations were monitored over
a period of 1 month.
The composition of each experimental vaccine is given
in Table 1. The commercial vaccine employed was Hyogen R©
(CEVA Santé Animale, Libourne Cedex, France) representing
a mineral oil emulsion with Escherichia coli J5 non-toxic LPS
as immunostimulant and inactivated M. hyopneumoniae field
isolate BA 2940-99 as antigen.
Animal Experiment
The study was performed after approval by the Ethical
Committee for Animal Experiments of the Faculty of Veterinary
Medicine, Ghent University (approval number EC2016/91).
Forty-two M. hyopneumoniae-free Rattlerlow-Seghers piglets
(RA-SE Genetics NV, Ooigem, Belgium) were enrolled in the
study. All animals were purchased from a herd that has been
free of M. hyopneumoniae for many years based on repeated
serological testing, nested PCR testing on tracheobronchial
swabs, and absence of clinical signs and pneumonia lesions in
the slaughter house. The piglets were weaned at 28 days of age
and transported 4 days later to the experimental facilities of the
Faculty of VeterinaryMedicine, Ghent University, Belgium. They
were housed in stables with absolute air filters for impending
particles (HEPAU15) on both incoming and outgoing ventilation
shafts and fed ad libitumwith a non-antimicrobial-supplemented
diet. On the day of arrival at the experimental facilities, the
piglets were randomly allocated into six vaccination groups and
one control group of six piglets each. Due to practical reasons,
the piglets were vaccinated, sampled and euthanized over 2
consecutive days. After an acclimatization period of 6 days, the
piglets of the vaccination groups were primo-vaccinated (D0; 39–
40 days of age) intramuscularly (IM) into the right side of the
neck with 2mL vaccine. Additionally, group Lipo_DDA:TDBwas
vaccinated intradermally (ID) into the left side of the neck with
0.2mL vaccine. The rationale for the ID injection of formulation
Lipo_DDA:TDB was based on a previous report showing
that CAF01, a liposome-based adjuvant containing similar
immunomodulators, was able to induce mucosal immunity when
administered this way (40). The piglets of the control group were
injected IM into the right side of the neck with 2mL sterile PBS.
Two weeks later (D14), the piglets of the vaccination groups
were booster vaccinated IM with 2mL vaccine (all groups).
The control group received 2mL PBS IM. On D28 all piglets
were euthanized.
Safety Parameters
The piglets were observed daily for at least 15min from D-6
until D28 of the study. On the days of vaccine administration,
the piglets were observed twice: shortly before (D0; D14)
and 4 h after vaccination (D0+4h; D14+4h). For each piglet,
clinical findings regarding body condition (skinny), behavior
(depressed, unconscious), respiration (sneezing, coughing,
abdominal breathing), digestion (diarrhea, vomiting), lameness
and other remarkable findings were recorded. At necropsy
(D28), lungs were macroscopically examined for the presence
of lesions according to Hannan et al. (41). Subsequently,
bronchoalveolar lavage (BAL) fluid was collected from one lung
part by flushing the head bronchus with 20mL sterile PBS,
as previously described (15). From the BAL fluid, DNA was
extracted using a commercial kit (DNeasy R© Blood & Tissue
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TABLE 1 | Composition of the experimental M. hyopneumoniae bacterins and their route of administration.
Vaccine formulation Dose (mL) Delivery system Immune-stimulators
(µg/dose)
Antigen dose (CCU) Administration route
Primo Booster
Lipo_AMP 2 DPPC:DC-Chol liposomes C-di.AMP (100) 109 IM IM
Lipo_TLR 2 DPPC:DC-Chol liposomes Pam3Cys-SK4/CpG ODN
SL03/resiquimod (80/80/80)
109 IM IM
PLGA_TLR 2 PLGA micro-particles (combined
to ethylaminoethyl-dextran)
Pam3Cys-SK4/CpG ODN
SL03/resiquimod (80/80/80)
109 IM IM
SWE_TLR 2 squalene-in-water emulsion Pam3Cys-SK4/CpG ODN
SL03/resiquimod (80/80/80)
109 IM IM
Lipo_DDA:TDB IM 2 ID 0.2 DDA liposomes TDB (500) IM 109 ID 2x108 IM+ID IM
CCU, color changing units; IM, intramuscular; ID, intradermal; DPPC:DC-Chol, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and dimethylaminoethane-carbamoyl-cholesterol; c-di-
AMP, bis-(3′,5′)-cyclic dimeric adenosine monophosphate; PLGA, poly(lactic-co-glycolic acid); DDA, dimethyl dioctadecylammonium; TDB, trehalose 6,6′-dibehenate.
kit, Qiagen, Venlo, The Netherlands) and a nested PCR for the
detection of M. hyopneumoniae DNA was performed according
to Stärk et al. (42).
The pigs were weighed on the day of primo-vaccination (D0)
and at euthanasia (D28). Average daily gain (ADG) in g/pig/day
was calculated according to Sacristán et al. (43).
Rectal body temperature was measured shortly before and 4 h
after vaccine administration, then daily until 4 days post-vaccine
administration, and on D7, 10, 21, 24, and 28 of the study. This
was based on the guidelines on safety evaluation of veterinary
vaccines written in the European Pharmacopeia 8.0.
Injection site reactions (ISR) were evaluated shortly before
vaccination, 4 h after vaccination and then daily from D1 to D28
using the scoring system explained in Supplementary Table 2.
Scores could range from 0 to 3 with 0 = normal, 1 = mild, 2 =
moderate, and 3 = severe. At euthanasia (D28), tissue samples
from the injection site were collected from all study animals
for histopathological examination. All IM and ID injection sites
were marked with a permanent pen upon vaccination. Out of
the marked area a tissue sample of approximately 2 cm2 with a
depth of 5 cm (IM injection site) or 3 cm (ID injection site) was
removed in an angle of 90◦ to the skin. A tissue sample with
a dimension of 2 × 2 × 3 cm from the left side of the neck
was collected as described above from the pigs of the control
group to serve as a control for the ID injection sites. The tissues
were fixed immediately after sampling in 10% neutral formalin.
After fixation, tissue blocks were sectioned from the samples,
embedded in paraffin and histological slides were stained with
hematoxylin and eosin. Each injection site sample was evaluated
using light microscopy and an overall score ranging from 0 to 3
(0 = not detected, 1 = mild, 2 = moderate, and 3 = severe) was
given. This score took into account the presence and degree of
hemorrhage, blood resorption, necrosis, inflammation (acute and
chronic), angiogenesis, and proliferation of connective tissue.
Serology
Before primo-vaccination (D0), on D7, on the day of booster
vaccination (D14) and at euthanasia (D28), serum samples were
collected and analyzed for the presence of antibodies against M.
hyopneumoniae with a commercial blocking ELISA (IDEIATM
Mycoplasma hyopneumoniae EIA kit, Oxoid Limited, Hampshire,
UK) according to the manufacturer’s instructions. Samples with
optical density (OD) lower than 50% of the average OD of the
buffer control were considered positive. Samples with OD-values
equal or bigger than 50% of the average OD of the buffer control
were classified as negative.
Immunoglobulin (Ig) G and IgA isotypes of the M.
hyopneumoniae-specific antibodies in serum were determined
with an in-house indirect ELISA. Briefly, Nunc Maxisorb R©
flat-bottom 96 well plates (eBioscience, San Diego, CA, USA)
were coated overnight at room temperature with Tween 20-
extracted M. hyopneumoniae antigens (44). After blocking with
PBS containing 0.05% Tween 20 and 1% BSA for 2 h at 37◦C,
plates were washed three times with PBS + 0.05% Tween 20
and serum diluted 1:200 and 1:100 was added for the detection
of IgG and IgA, respectively. After incubating for 30min at
37◦C, plates were washed again, and peroxidase-labeled goat anti-
porcine polyclonal IgG diluted 1:60,000 and IgA diluted 1:20,000
(Bethyl Laboratories, Montgomery, TX, USA) were added. Plates
were incubated again for 30min at 37◦C, washed and 3,3′5,5′-
tetramethylbenzidin substrate (Sigma-Aldrich, Saint Louis, MO,
USA) was added. After incubating for 10min, the reaction was
stopped with 2N HCl and the OD was measured at 450 nm.
All samples were tested in duplicate. To relatively quantify
the antibody levels a standard curve was made using two-fold
serial dilutions of a positive reference serum corresponding
to defined arbitrary units (1:800 dilution defined as 1 unit).
The interpolation from the standard curve employed non-linear
regression with least square fits using Graphpad Prism 7.0
(GraphPad Software Inc., San Diego, CA, USA).
M. hyopneumoniae-Specific Antibodies in
Bronchoalveolar Lavage (BAL) Fluid
The BAL fluid collected on D28 was analyzed undiluted for
the presence ofM. hyopneumoniae-specific IgA antibodies using
peroxidase-labeled goat anti-porcine polyclonal IgA (Bethyl
Laboratories, Montgomery, TX, USA) diluted 1:80,000 in an in-
house indirect ELISA as described above. A cut-off was calculated
as mean OD-value from the control animals plus three times
Frontiers in Immunology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 1087
Matthijs et al. Immunological Characterization of Novel Mycoplasma hyopneumoniae Bacterins
the SD and established at an OD-value of 0.098. Samples with
OD-values higher than the cut-off were considered positive and
samples equal to or below the cut-off were considered negative.
T Cell Assays
Shortly before the booster vaccination on D14 and on the day of
euthanasia (D28), blood samples were taken from each animal to
assess the primary and secondary T cell-specific responses against
M. hyopneumoniae. For each animal, samples were restimulated
in triplicate cultures and analyzed separately. Briefly, peripheral
blood mononuclear cells (PBMCs) were isolated using a ficoll-
plaque density gradient (1.077 g/L, GE Healthcare Bio-sciences
Corp., Piscataway, NJ, USA) and plated in 12-well plates at 5 ×
106 cells/well in 1ml of AIM-Vmedium (GibcoTM, ThermoFisher
Scientific, Waltham, MA, USA). Subsequently, the cells were
restimulated in vitro overnight (18 h) with 6.25× 107 CCU/mL of
M. hyopneumoniae F7.2C bacterin. For the last 4 h of stimulation,
we added Brefeldin A (eBioscience, San Diego, CA, USA) in
each well to inhibit cytokine release and allow intra-cellular
detection of cytokines by flow cytometry (FCM). Concanavalin
A stimulation (10µg/mL, Sigma-Aldrich, Saint Louis, MO, USA)
was employed as a positive control. Cells were then harvested and
the cytokine production of T cell populations was determined
by FCM, using a 5-step 6-color staining protocol. Cells were
first incubated with the LIVE/DEADTM Fixable Aqua Dead Cell
Stain Kit (InvitrogenTM, ThermoFisher Scientific, Waltham, MA,
USA) according to the manufacturer’s instructions. The cells
were then incubated with anti-CD4 (clone 74-12-4, Southern
Biotech, Birmingham, AL, USA) and anti-CD8β (clone PG164A,
WSU, Pullman, WA, USA) antibodies, and subsequently with
the corresponding secondary antibodies: anti-mouse IgG2b
AlexaFluor 488 (Molecular Probes, Eugene, OR, USA) and anti-
mouse IgG2a PE-Cy7 (Abcam, Cambridge, UK), respectively.
Following surface staining, cells were fixed and permeabilized
using the BD Cytofix/CytopermTM Fixation/Permeabilization
Solution kit (Becton Dickinson, Franklin Lakes, NJ, USA)
according to the manufacturer’s instructions. Cells were finally
incubated with directly coupled anti-human TNF-α AlexaFluor
647 (clone MAb11, BioLegend, San Diego, CA, USA), anti-pig
IFN-γ PerCP-Cy5.5 (clone P2G10, Becton Dickinson, Franklin
Lakes, NJ, USA), and anti-human IL-17A PE (clone SCPL1362,
Becton Dickinson, Franklin Lakes, NJ, USA). Flow cytometry
acquisition was performed on a CytoFLEX flow cytometer
(Beckman Coulter, Brea, CA, USA) and the results were further
analyzed with the FlowJoTM software (Tree Star Inc., Ashland,
OR, USA).
Vaccine-Induced Transcriptional
Responses
Blood samples were collected on D0, D1, and D7 for RNA
preparation (2.5ml in PAXgene R© Blood RNA Tubes, Becton
Dickinson, Franklin Lakes, NJ, USA). RNA was extracted
using the Paxgene R© Blood RNA kit (Qiagen, Venlo, The
Netherlands) and the RNA quality was controlled with a
Fragment Analyzer. All samples were found to have good quality
[RNA integrity number (RIN) > 8] and were sequenced using
an Illumina R© HiSeq 3000 sequencer (Illumina, San Diego, CA,
USA). The quality of the reads was assessed using FastQC v.
0.11.21 The reads were mapped to the Sus scrofa reference
genome (Sscrofa_11.1) with HISAT2 v. 2.1.0 (45). Feature Counts
from Subread v. 1.5.3 was employed to count the number
of reads overlapping with each gene, as specified in the
Ensembl annotation build 91. The RNAseq data are available
in the European Nucleotide Archive2 under the accession
number PRJEB30361.
The Bioconductor package DESeq2 v. 1.18.1 was used to
test for differential gene expression between the different time
points for each vaccine separately (46). Our specific interest was
to identify genes where the change between two time points
was different in vaccinated animals compared to the controls.
Therefore, a two-factorial model was used, including the factors
time point and group (vaccine vs. control), and their interaction.
The genes were then ranked based on the P-values for the
interaction term for a “ranked gene set enrichment analysis”
(GSEA) (47) using the BTM as defined by Li et al. (48).
The BTM were adapted to the pig by replacing human genes
with their pig homologs. This step involved extensive manual
curation. The final lists of genes for each module can be found
in theData Sheet 1.
To compare the module activity of the different vaccines,
all modules with a false discovery rate (FDR) q < 0.1 were
used. In GSEA, a cut-off of 0.25 is recommended but in this
study a cut-off of 0.1 was selected to reduce the amount of
BTM changing over time. Heat maps were created reflecting
the modular activity calculated as the negative natural logarithm
of the P-value. For negative enriched BTM, this was multiplied
with −1 to obtain a positive value. The rationale of this was to
obtain a value reflecting both the enrichment of a module and its
statistical significance.
Correlation Analyses of BTM and
Vaccine-Induced Adaptive
Immune Responses
To get more insight in the immunomodulation toward a
potent immune response, BTM were correlated with the
vaccine-induced adaptive immune responses (antibodies, M.
hyopneumoniae-specific INFγ+TNF+ CD4T cells and CD8T
cells). To this end, single-sample (ss) GSEA scores were first
calculated to transform a single sample’s gene expression profile
to a gene set (BTM) enrichment profile3 as described in
Barbie et al. (49). Subsequently, the time-dependent changes
in ssGSEA values for each BTM were determined as the
ratio of D1:D0, D7:D0, and D1:D7 ssGSEA values. These
ratios were then correlated to the immune response values
using Pearson’s correlation coefficient. In order to obtain
sufficient values, the data from all vaccinated animals (controls
excluded) was used. Only correlation coefficients with P < 0.05
were considered.
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
2www.ebi.ac.uk/ena
3http://software.broadinstitute.org/cancer/software/genepattern/modules/docs/
ssGSEAProjection/4
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Statistical Analyses
Fisher’s exact tests were performed to analyse differences in
the number of animals with ISR and histopathological findings
(irrespective of type) at the injection site between the control
group and the vaccinated groups. A Bonferroni correction
for multiple tests was applied. Rectal temperature values were
averaged for the following periods: D1-3, D4-14, D15-17, and
D18-28 to distinguish between systemic reactions shortly after
vaccination (D1-3; D15-17) and systemic reactions developed
later on (D4-14; D18-28). Rectal temperature and ADG were not
normally distributed according to the Shapiro-Wilk’s test, and
Mann-Whitney U tests were run to analyse differences between
the control and vaccinated groups in ADG, rectal temperature
measured 4 h after vaccination (D0+4h; D14+4h) and during the
following periods: D1-3, D4-14, D15-17, D18-28. The Bonferroni
method was applied to correct for multiple comparisons. For
the quantitative antibody ELISA and T cell data, a two-way
ANOVA was employed using the factors vaccine and time.
Tukey’s or Dunnett’s tests were used to correct for multiple
comparisons, respectively. Statistical analyses of clinical variables
were conducted in SPSS 24 for Windows (IBM, Armonk, NY,
USA) and for immune response data using GraphPad Prism 7.0
(GraphPad Software Inc., San Diego, CA, USA). Significance is
indicated as ∗P ≤ 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
RESULTS
Safety of the Vaccines
To evaluate the safety of the vaccines the general health, ADG and
rectal temperature of the piglets was closely monitored. Diarrhea,
which sometimes resulted in skinny pigs, was the most frequent
clinical finding observed in all groups (Lipo_DDA:TDB: 2/6;
Hyogen and PLGA_TLR: 4/6; control, Lipo_TLR, SWE_TLR:
5/6; Lipo_AMP: 6/6; Supplementary Figure 1B). As it was
mostly seen during the acclimatization period and started the
day after arrival, it was diagnosed as post-weaning diarrhea.
All pigs were treated once with 5mg enrofloxacin per kg
body weight (Floxadil R© 50 mg/mL, Emdoka, Hoogstraten,
Belgium) IM in the hind leg and responded well on treatment.
Arthritis (swollen joints) was also observed (control, Lipo_AMP,
Lipo_TLR, PLGA_TLR: 1/6; Hyogen: 3/6) and cases occurred
during the whole study period (Supplementary Figure 1C).
Bursitis was recorded for one pig in groups Lipo_TLR, SWE_TLR
and Hyogen, and lameness for one pig in groups Lipo_AMP
and Lipo_DDA:TDB (Supplementary Figures 1D–E). Behavior
and respiration were normal throughout the entire study, except
for one pig of the PLGA_TLR group that showed severe
abdominal breathing following blood sampling on D14. At
necropsy (D28), none of the pigs had macroscopic lung lesions
and no M. hyopneumoniae DNA was detected in BAL fluid.
The vaccinated groups did not differ in ADG compared to
the control group (data not shown). Four hours after primo-
and booster vaccination (D0+4h, D14+4h), rectal temperatures
of groups SWE_TLR and Hyogen were significantly higher
compared to the control group (P ≤ 0.05). Rectal temperatures
from Lipo_AMP and Lipo_TLR were also increased over
the physiological threshold (>40◦C) 4 h after primo- and
booster vaccination. However, this increase was only statistically
significant compared to the control group at D0+4h and D14+4
for groups Lipo_TLR and Lipo_AMP, respectively (P ≤ 0.05). A
slight increase, although not statistically significant, was observed
for PLGA_TLR 4 h after primo-vaccination. Group means were
back to normal 1day after vaccination and all remained within
normal physiological levels during the remainder of the trial
(Supplementary Figure 1F).
The presence and severity of ISR was recorded daily and
a histopathological examination of each injection site was
performed at the end of the study (D28). No ISR were seen
in the control group and group PLGA_TLR. Overall mild and
transient ISR were observed in one pig of group SWE_TLR,
and in two pigs of each of the groups Lipo_AMP, Lipo_TLR,
and Hyogen. In the group Lipo_DDA:TDB three pigs showed
a moderate but transient ISR at the IM injection site. However,
at the ID injection site, all pigs showed a prolonged mild to
moderate ISR which lasted until the end of the study in 4/6 pigs.
A more detailed overview of the duration of the ISR and their
severity is given in Supplementary Table 3. Histopathological
examination of the injection site at D28 revealed an overall severe
foreign body reaction with chronic inflammation, angiogenesis,
and proliferation of connective tissue in 5/6 ID injection site
samples from group Lipo_DDA:TDB.Mild (moderate for one pig
in group SWE_TLR) focal chronic inflammation was observed
in all IM injected groups. Mild to moderate hemorrhage was
also observed in all IM injected groups. This was probably
caused by the sampling itself as it was most of the time
located at the borders of the collected tissue. The results of
the histopathological examination of the injection sites are
represented in Supplementary Table 4.
M. hyopneumoniae-Specific
Antibody Responses
According to the commercial blocking ELISA (Oxoid;
Supplementary Table 5), all pigs from the control group
remained serologically negative for M. hyopneumoniae
throughout the study. On day 28 of the study, all the animals from
groups Lipo_AMP, Lipo_TLR, SWE_TLR, Lipo_DDA:TDB, and
Hyogen were seropositive. From the PLGA_TLR group, only
two out of six pigs seroconverted at D28.
To quantify serum IgG levels in arbitrary units we used
an in-house indirect ELISA with a positive reference serum as
a standard (Figure 1). At D28, groups Lipo_AMP, SWE_TLR,
Lipo_DDA:TDB, and Hyogen were statistically different from
the control group. The Lipo_DDA:TDB formulation induced the
highest IgG response, followed by the Hyogen and Lipo_AMP
formulations. Group Lipo_TLR was not significantly higher than
the control group, although we could detectM. hyopneumoniae-
specific IgG antibodies in all animals from this group. In the
PLGA_TLR group, only one animal appeared to react. No M.
hyopneumoniae-specific IgA antibodies were observed for any of
the groups at any time point in the serum. Only one animal from
the SWE_TLR group was positive forM. hyopneumoniae-specific
IgA in BAL fluid on D28 (Supplementary Table 3).
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FIGURE 1 | Serum antibody levels following vaccination of pigs with vaccine candidates. M. hyopneumoniae-specific IgG antibodies induced by the five novel
vaccines and one commercial vaccine listed in the legend were determined by indirect ELISA. Six animals per group received two injections in 14 days interval.
Individual animals are shown. Significance was calculated using two-way ANOVA followed by Tukey’s test (*P < 0.05; **P < 0.01; ***P < 0.001).
T Cell Responses
The results of the M. hyopneumoniae-specific T cell responses
after primo-vaccination (D14) are presented in Figures 2A–C.
No significant group differences were found for the percentage of
cytokine-producing T cells in the peripheral blood compartment.
Nevertheless, as antigen-specific T cells are transient in the blood,
a negative result cannot be interpreted as a lack of T cell response.
In fact, a few animals appeared to respond (defined as being above
the 99% confidence interval (CI) of the control group) indicating
some degree of T cell priming in certain groups. This was
found in particular in the groups SWE_TLR, Lipo_DDA:TDB
and Hyogen with three animals above this threshold for the
TNF+IFN-γ+ double positive CD4 (Th1) cells (Figure 2A). For
the CD8+ TNF+IFN-γ+ T cells, two animals were above the
threshold in the PLGA_TLR, SWE_TLR, and Hyogen groups
(Figure 2C).
At D28, the SWE_TLR and Lipo_DDA:TDB groups were
significantly higher than the control group for the percentage
of CD4+ TNF+IFN-γ+ T cells (Figure 2D) and the PLGA_TLR
group was significantly higher than the control group for the
percentage of CD4+IL17A+ (Th17) cells (Figure 2E). For the
percentage of CD8+ TNF+IFN-γ+ T cells, groups Lipo_AMP
and lipo_DDA:TDB were significantly higher compared to the
control animals (Figure 2D). Despite the lack of statistical
significance, other vaccines also appeared to have induced
specific T cell immunity in some animals. For the CD4+
TNF+IFN-γ+ cells, three animals were above the 99% CI
threshold in the Lipo_AMP group and two in the Hyogen group.
For the CD8+ TNF+IFN-γ+ cells, two pigs were above the 99%
CI threshold in the Lipo_TLR group, five in the SWE_TLR group
and three in the Hyogen group (Figures 2D–F).
When focusing on TNF−IFN-γ+-producing T cells, we
found a high level of non-specific responses at both D14
and D28 in the unvaccinated group which “masked” the
vaccine induced responses (Supplementary Figure 2). Only
Lipo_DDA:TDB induced a significant level of CD4+ TNF+IFN-
γ−-producing T cells at D28 (Supplementary Figure 3).
In conclusion, the vaccines SWE_TLR and Lipo_DDA:TDB
induced a statistically significant Th1 driven T cell response. In
the groups receiving the Hyogen and Lipo_AMP formulations,
despite a trend suggesting stimulation of Th1 responses, the
differences were not statistically significant in the current
setting. Interestingly, the PLGA_TLR formulation was the
only vaccine candidate which significantly induced a Th17
response, although only 3/6 animals in this group were above
the threshold.
Blood Transcriptional Modules Correlating
to Vaccine-Induced Adaptive
Immune Responses
In order to shed light on the immunological perturbations
associated with adaptive immune responses, changes in
transcriptional modules expression were correlated to the
immune responses shown in Figures 1, 2.
For the early transcriptional responses (determined as
modular changes between D0 and D1), a total of seven
inflammatory, eight myeloid cell, three DC/antigen presentation
and one IFN type I BTM correlated positively with the antibody
response. Interestingly, none of these modules correlated with
the CD4T cell response, but some with the CD8T cell response.
For the late transcriptional responses (determined as modular
changes between D1 and D7), a negative correlation was found
for many BTM belonging to the families of modules reflecting
innate immune responses. This was found again mainly for the
antibody and CD8T cell responses (Figure 3).
Main positive correlations of the CD4T cell response were the
D0 to D7 changes in cell cycle BTM (Figure 4). For the change of
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FIGURE 2 | M. hyopneumoniae-specific T cell responses induced following vaccination of pigs with vaccine candidates. Six animals per group were prime-boost
vaccinated on D0 and D14. At D14 and D28, M. hyopneumoniae-specific T cells induced by the tested vaccines listed in the legend were determined by in vitro
restimulation of PBMC from vaccinated animals followed by intracellular cytokine staining and multicolor flow cytometry. Following doublet exclusion, live cells were
gated and the percentage of IFNγ+TNF+ double positive CD4+ (A,D) and CD8β+ (C,F) T cells as well as IL-17A+ CD4T cells (B,E) was determined. The mean
values obtained from triplicate cultures for individual animals are shown. Positive animals are marked in red (defined as being above the 99% CI of the control group).
Significance was calculated using two-way ANOVA followed by Dunnett‘s test (*P < 0.05; **P < 0.01; ***P < 0.001). PBMC, peripheral blood mononuclear cells.
cell cycle BTM between D1 and D7, we also found many modules
correlating with antibody and T cell responses.
T/NK cell BTM upregulation between D0 and D7 correlated
well with CD8T cell responses. The induction of these BTM also
correlated with antibody levels between D1 and D7 (Figure 4).
Transcriptional Profiling of Vaccines
To better understand differences in the induction of immune
responses between the vaccines, we next performed a
transcription profiling. From the reads obtained, we first
calculated the differentially expressed genes (DEG) using
DSeq2, and then employed a two-factorial model, including the
factors time point and group (vaccine vs. control), to identify
genes differing between two time points in vaccinated animals
compared to the controls. Next, we used ranked GSEA analyses
using BTM as gene sets and ranked DEG between D0 and D1,
D0 and D7, and D1 and D7 of each vaccine group. All data are
shown in Figures 5–8 and Supplementary Figures 4, 5, and
summarized in Table 2.
Inflammatory Responses
From D0 to D1, the Lipo_AMP formulation induced the
highest number of inflammatory BTM, followed by the groups
SWE_TLR and Lipo_DDA:TDB (Figure 5). Interestingly, in
the PLGA_TLR group, no inflammatory BTM were induced
and some even showed a downregulation. For the D0 to D7
comparison, again groups Lipo_AMP and SWE_TLR showed
the highest upregulation of these BTM. For the D1 to D7
comparison, we found a downregulation of inflammatory
modules in the Lipo_AMP, Lipo_TLR, and the Hyogen groups
but not in the Lipo_DDA:TDB group, which still had BTM
related to platelet activation overexpressed. In the PLGA_TLR
group, eight BTM were upregulated indicating a delayed innate
immune response. In summary, the three vaccines which
induced significant T cell responses in terms of IFNγ/TNF
secreting cells as well as antibody responses were those
with the strongest positive early upregulation of inflammatory
BTM, confirming the results obtained using the correlation
analysis (Figure 3).
IFN Type I Responses
With respect to IFN type I BTM, only vaccines which
contained IFN inducers such as c-di-AMP (Lipo_AMP) and
CpG (Lipo_TLR, SWE_TLR) induced an early IFN type I BTM
response. The PLGA_TLR formulation contained the same TLR
cocktail as SWE_TLR and Lipo_TLR, but was unable to induce
such responses (Figure 5).
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FIGURE 3 | Innate immune response BTM correlating with adaptive immune responses. Time-dependent changes in scores for BTM were determined using ssGSEA
and then correlated to antibodies, M. hyopneumoniae-specific INFγ+TNF+ CD4T cells and CD8T cells. Pearson correlation coefficients for the BTM changes from
D0 to D1 (D0 vs. D1), from D0 to D7 (D0 vs. D7), and from D1 to D7 (D1 vs. D7) are shown as heat maps. A P < 0.05 was used as cut-off. Red colors indicate positive
and blue negative correlations. The BTM were grouped into inflammatory, myeloid cell, DC/antigen presentation and IFN type I BTM as previously described (34).
BTM, blood transcriptional modules.
Myeloid and DC/Antigen Presentation Responses
All vaccines with the exception of PLGA_TLR induced an
early (D0 to D1) myeloid cell response (Figure 6). The number
of BTM being modulated was the highest in the Lipo_AMP
group, followed by the groups SWE_TLR, Lipo_DDA:TDB, and
Hyogen (the latter two being very similar). The PLGA_TLR
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FIGURE 4 | Cell cycle and lymphocyte BTM correlating with adaptive immune responses. Time-dependent changes in scores for BTM were determined using ssGSEA
and then correlated to antibodies, M. hyopneumoniae-specific INFγ+TNF+ CD4T cells and CD8T cells. Pearson correlation coefficients for the BTM changes from
D0 to D1 (D0 vs. D1), from D0 to D7 (D0 vs. D7) and from D1 to D7 (D1 vs. D7) are shown as heat maps. A P < 0.05 was used as cut-off. Red colors indicate positive
and blue negative correlations. The BTM were grouped into cell cycle, T/NK cell and B cell BTM as previously described (34). BTM, blood transcriptional modules.
formulation actually had a negative influence on myeloid
cell BTM response. Only Lipo_AMP, Lipo_TLR, and Hyogen
induced a clear downregulation of these BTM from D1 to
D7. This was interesting considering that a late D1 to D7
downregulation of myeloid cell BTM was found to strongly
correlate with antibody and CD8T cell responses (Figure 3). In
summary, the vaccines which induced good adaptive immune
responses were also those which induced an early induction of
many myeloid cell BTM.
The Lipo_AMP formulation was found to be the most
potent to induce BTM relating to DC and antigen presentation
from D0 to D1. Similar to the myeloid cell BTM, DC/antigen
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FIGURE 5 | Inflammatory and IFN type I BTM induced by vaccines. The heat maps show the vaccine-dependent induction of BTM activity determined for D0 to D1
(D0 vs. D1), for D0 to D7 (D0 vs. D7), and for D1 to D7 (D1 vs. D7) changes in the modules. The values shown were calculated by −log(P-value)*1 for positively
enriched BTM and as −log(P-value)* −1 for negatively enriched BTM. A cut-off of an FDR of q < 0.1 was employed. Red colors indicate BTM upregulation and blue
downregulation. BTM, blood transcriptional modules.
presentation BTM were downregulated from D1 to D7 by the
formulations Lipo_AMP and Lipo_TLR, and to a lower extent
by the Hyogen vaccine.
Cell Cycle/Proliferation
The Lipo_DDA:TDB and SWE_TLR vaccines were found to
downregulate, while PLGA_TLR upregulated cell cycle BTM
from D0 to D1 (Figure 7). The two liposomal formulations
Lipo_AMP and Lipo_TLR had a clear positive effect on these
BTM at later time points (D0 to D7 and D1 to D7). Interestingly,
the correlation analyses demonstrated a clear association between
the late (D0 or D1 to D7) upregulation of these BTM and adaptive
immune responses (Figure 4).
B Cell BTM and T/NK Cell BTM
The Lipo_AMP, SWE_TLR, and Hyogen vaccines had an overall
negative effect on the early expression (D0 to D1) of B-cell
BTM (Figure 8). The SWE_TLR and Hyogen formulations were
those to strongly induce these BTM at later time points (D1
to D7). Common BTM between the strong vaccines in terms
of antibody responses were plasma cells and immunoglobulin
(M156.0 and M156.1), which were overexpressed from D1 to D7.
However, these BTMwere not found significant in the correlation
analyses (Figure 4).
For the T cell/NK cell BTM, a variable early downregulation
by the more immunogenic vaccines Lipo_AMP, SWE_TLR,
Lipo_DDA:TDB, and Hyogen was found. Only the liposomal
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TABLE 2 | Overview of the immune responses induced by the M. hyopneumoniae bacterins.
Vaccine formulation Ab
response
(D28)
Th1
response
(D14/D28)
Th17
response
(D14/D28)
Early
inflam.
BTM
Early
IFN type I
BTM
Early
myeloid
cell/DC BTM
Late cell
cycle BTM
Late
T/NK-cell
BTM
Late Ig
BTM
Lipo_AMP ++ + – +++ + +++ ++ ++ ++
Lipo_TLR + + – + + + ++ ++ ++
PLGA_TLR – – + – – – – – –
SWE_TLR + ++ – ++ ++ ++ – – +++
Lipo_DDA:TDB ++ +++ – + – ++ – – ++
Hyogen ++ + – + – ++ – – ++
Six animals per group were prime-boost vaccinated on D0 and D14. Ab, antibody; Th, T helper; BTM, blood transcriptional modules; early, upregulation from D0 to D1; late, upregulation
from D1 to D7; –, none to weak; +, moderate; ++, strong; +++, very strong.
formulations Lipo_AMP and Lipo_TLR induced a late D0/D1
to D7 upregulation of these modules, although many of those
modules correlated to antibody and T cell responses (Figure 4).
DISCUSSION
The present study assessed the safety and performed a detailed
immunological profiling of five novel M. hyopneumoniae
bacterin formulations. We included as well the commercial
vaccine Hyogen R© in our study. Hyogen R© is a recently developed
bacterin based on a virulentM. hyopneumoniae field isolate with
a TLR4 ligand as immunostimulant, and in that way comparable
with our experimental bacterin formulations.
In terms of side effects, formulations Lipo_AMP, Lipo_TLR,
and SWE_TLR induced a significant but transient increase in
rectal body temperature shortly (4 h) after vaccination. This
was also observed for the Hyogen R© vaccine, and comparable
observations were made by Llopart et al. (50) after two shot
vaccination against M. hyopneumoniae with the commercial
vaccine Mypravac suis R© (HIPRA, Amer, Spain). Fever beginning
a few hours after vaccination and persisting for 24 to 36 h
is the result of an excessive induction of pro-inflammatory
cytokines by the vaccine (51, 52). Systemic reactions of such
kind are commonly reported and considered as “normal toxicity”
associated with vaccination (52).
Overall, the ISR occasionally observed in all IM vaccinated
groups and at the IM injection site of group Lipo_DDA:TDB
weremild and resolved quickly. Transient redness and swelling at
vaccination sites were also reported in other M. hyopneumoniae
vaccination studies (53–55). Such local reactions often occur
after parenteral administration of adjuvanted vaccines and are
tolerated in terms of safety (52). Microscopically, mild focal
chronic inflammation was observed in all IM injected groups,
including the control group, indicating that these findings were
probably caused by the tissue damage due to needle insertion
and injection of fluid, and not by the administered vaccine
formulation. Nevertheless, prolonged mild to moderate ISR were
observed in all pigs from group Lipo_DDA:TDB at the ID
injection site and histopathological examination of this injection
site at D28 of the study showed a severe foreign body granuloma
in five pigs. Local reactions of such kind could result in carcass
trim losses at slaughter and are therefore considered to be a
relevant adverse side effect of vaccination (51, 56). The transient
ISR at the IM injection site of this vaccine group suggests that the
prolonged and rather severe ISR is at least partially due to the ID
administration. However, this cannot be stated with certainty as
there was no control group ID injected with sterile PBS.
Two weeks after booster vaccination, the commercial vaccine
Hyogen R© as well as the vaccines Lipo_DDA:TDB and Lipo_AMP
induced a strong humoral response. Vaccine formulations
SWE_TLR and Lipo_TLR generated a moderate serological
response, whereas for the PLGA_TLR formulation only two
animals seroconverted. Nevertheless, as we do not know the
antigen payload of the Hyogen R© vaccine, we cannot directly
compare its efficacy to the experimental vaccines. Although
systemic antibodies are considered to play a minor role in
protection against EP (5, 13), high levels of serum antibodies
induced by vaccination can be an easy and practical tool to
confirm successful vaccination in the field (57). It can also
be expected that high levels of IgG will only be induced
with significant induction of Th cell activation. We only
found lgA antibodies in BAL fluid of one pig injected with
the SWE_TLR vaccine. This is not surprising considering
the parenteral vaccine administration, and is in line with
previous studies showing IgA in BAL fluid of vaccinated pigs
only after challenge (13, 14). Future studies are required to
investigate the potential of adjuvants to induce both local and
systemic immune responses after mucosal application of the
vaccine. For example, this has been achieved for inactivated
viruses using nanoparticle-based delivery (58, 59). Nevertheless,
the absence of detectable IgA antibodies in BAL fluid from
vaccinated pigs does not exclude priming of the immune
system for such responses as vaccinated animals had higher
mucosal IgA responses compared to unvaccinated animals
following challenge (13, 14). Although we did not measure
M. hyopneumoniae-specific IgG in BAL fluid, it can reach
the alveolar lumen by transudation from the blood and
might also play a role in protection against disease. In fact,
the implementation of the human parenterally-administered
conjugate vaccine against type B Haemophilus influenza resulted
in a reduction of carriage and a reduced risk of horizontal
transmission. This was hypothesized to be due to such
IgG (60, 61).
Circulating M. hyopneumoniae-specific TNF+IFN-γ+ CD4
and CD8T cells were identified in particular in the SWE_TLR,
Frontiers in Immunology | www.frontiersin.org 12 May 2019 | Volume 10 | Article 1087
Matthijs et al. Immunological Characterization of Novel Mycoplasma hyopneumoniae Bacterins
FIGURE 6 | Myeloid cell and DC/antigen presentation BTM induced by vaccines. The heat maps show the vaccine-dependent induction of BTM activity determined
for D0 to D1 (D0 vs. D1), for D0 to D7 (D0 vs. D7), and for D1 to D7 (D1 vs. D7) changes in the modules. The values shown were calculated by −log(P-value)*1 for
positively enriched BTM and as −log(P-value)* −1 for negatively enriched BTM. A cut-off of an FDR of q < 0.1 was employed. Red colors indicate BTM upregulation
and blue downregulation. BTM, blood transcriptional modules.
Lipo_DDA:TDB, and Lipo_AMP groups. However, also in the
Lipo_TLR and Hyogen groups a few animals appeared to have
such cells. Such Th1 response is expected to promote cell-
mediated immunity via activation of NK cells and macrophages,
as well as by inducing antigen-specific cytotoxic immunity (CD8
cells) (62). While such responses could participate in protection
againstM. hyopneumoniae, pro-inflammatory CD4 Th responses
might also mediate lung damage and clinical disease (63). While
the classical effector functions of CD8T cells are likely irrelevant
for the immune response against a Mycoplasma species that
is not an intracellular organism, mouse models indicate that
CD8T cells are suspected to dampen inflammatory responses
mediated by CD4+ Th cells (24, 64). Furthermore, CD8T cells
contribute to Th1 responses, which based onmousemodels could
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FIGURE 7 | Cell cycle BTM induced by vaccines. The heat maps show the vaccine-dependent induction of BTM activity determined for D0 to D1 (D0 vs. D1), for D0
to D7 (D0 vs. D7), and for D1 to D7 (D1 vs. D7) changes in the modules. The values shown were calculated by −log(P-value)*1 for positively enriched BTM and as
−log(P-value)* −1 for negatively enriched BTM. A cut-off of an FDR of q < 0.1 was employed. Red colors indicate BTM upregulation and blue downregulation. BTM,
blood transcriptional modules.
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FIGURE 8 | B cell and T/NK cell BTM induced by vaccines. The heat maps show the vaccine-dependent induction of BTM activity determined for D0 to D1 (D0 vs.
D1), for D0 to D7 (D0 vs. D7), and for D1 to D7 (D1 vs. D7) changes in the modules. The values shown were calculated by −log(P-value)*1 for positively enriched BTM
and as −log(P-value)* −1 for negatively enriched BTM. A cut-off of an FDR of q < 0.1 was employed. Red colors indicate BTM upregulation and blue downregulation.
BTM, blood transcriptional modules.
be protective against Mycoplasma infection. Based on this their
induction by the present vaccines could be viewed as positive.
In this study, the PLGA_TLR formulation was the best at
inducing a Th17 response, although in only three of six animals a
response was detected. The lack of detection of IL-17-producing
Th cells does not mean a lack of priming, as activated/memory
T cells could have left the blood circulation. Nevertheless, future
studies are required to confirm the ability of this formulation to
induce Th17 responses. It has been suggested that Th17 cells may
play a major role in the protection of the lung mucosa against
respiratory pathogens by recruiting other immune cells to the
inflamed mucosa for pathogen clearance (65) and by promoting
IgA secretion into the airway lumen (66). Similar to other species,
porcine IL-17-producing cell differentiation can be induced in
vitro by TGF-β in the presence of IL-6 and/or IL-1β (67), and
in vivo during several extracellular bacterial infections (68–70).
In addition to these classical vaccinology readouts we also
applied a transcriptomics-based approach to obtain a more
precise profile of the type of immune response induced by
our vaccine candidates, and to better understand the immune
modulatory effector functions needed for induction of a
protective immune response after vaccination. We identified
a number of BTM correlating to adaptive immune responses
which have been previously reported in human and sheep
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studies (25, 26, 28–30, 34). This was an early upregulation
of monocytes BTM, such as S4, M11.0, M118.0, and M118.1,
neutrophil BTM such as M163 and M37.1, modules related to
inflammation and pathogen sensing such as M16, M146, and
M37.0, and BTM related to antigen presentation such as M147,
M139, and M209. Interestingly, many of these modules strongly
negatively correlated with the antibody and CD8T cell responses
from D1 to D7. This suggests that a strong innate immune
response in the first 24 h followed immediately by a down-
regulation is associated with the initiation of a stronger adaptive
immune response. This inverse correlation was also seen at later
time points in a previous study using sheep (34). Similar to
previous reports (25, 28, 29, 34) a few cell cycle, B cell, and
T/NK cell BTM upregulated in the first 24 h after vaccination
negatively correlated with adaptive immune responses. While
these correlations were mainly found for the antibody responses,
most of the modules correlating to CD4T cell responses were
found to be cell cycle BTM upregulated between D0 and D7.
This was also reported by Qi et al. (30) who found a strong
association of cell cycle and DNA repair BTM to virus-specific
T cells (common BTM are M4.4, M4.12, M103, M76, M22.0,
M22.1). The upregulation of T/NK cell modules between D0 and
D7 positively correlated to CD8T cell responses, as well as to the
antibody responses between D1 and D7. Altogether, these results
confirm the importance of early innate immune responses in the
myeloid and DC cell compartment within the first 24 h for a
potent vaccine-induced adaptive immune response. Clearly, the
upregulation of myeloid cell and DC/antigen presentation BTM
could partially reflect changes in cell population, i.e., those that
are caused by enhanced hematopoiesis following stimulation of
the innate immune system (71). Nevertheless, in a previous study
we were unable to identify a significant increase in the circulation
of monocytes, indicating that the BTM changes reflect more than
changes in cell populations (34). This study also demonstrates
that the main upregulated BTM from D0 or D1 to D7 correlating
to adaptive immune responses are cell cycle and T/NK cell BTM.
This could reflect the first recirculation of activated T cells leaving
the lymph nodes that drain the site of vaccine injection.
After obtaining this information, we went back and analyzed
which BTM were actually induced by the vaccines. While all
vaccines, with the exception of the PLGA_TLR formulation,
induced early upregulation of inflammatory, myeloid cell and
DC/antigen presentation BTM, the Lipo_AMP vaccine appeared
to be the most potent in stimulating these early innate immune
responses. When it came to the later upregulation of cell cycle
and T/NK cell BTM, this was only a feature of the Lipo_AMP and
the Lipo_TLR vaccines. This was surprising considering that the
Lipo_TLR was not found to be a particularly potent formulation.
Furthermore, the more potent vaccines, such as Lipo_DDA:TDB
and SWE_TLR, actually induced a downregulation of these
BTM. While this requires further investigations, our current
interpretation is that there could be differences in the kinetics of
activated lymphocyte recirculation, which would have required
more frequent sampling to detect. Furthermore, it should again
be noted that T cell recirculation and the presence of memory
T cells in the circulation is a dynamic process. Therefore, a lack
of antigen-specific T cells in the peripheral blood cannot be
interpreted as a lack of priming. On the other hand, the BTM
profile induced by the PLGA_TLR vaccine was in line with its
rather poor immunogenicity.
Overall, our data demonstrate the potency of cationic
liposome formulations as delivery system to induce potent B
and T cell responses using inactivated M. hyopneumoniae as
antigen. Cationic liposomes may have the advantage of a more
targeted delivery of the immunostimulant and antigen to DC,
and also have been shown to enhance the retention time in
lymph nodes (72, 73). This may favor strong T cell responses.
Although we did not specifically address the requirement of an
immunostimulant for liposomal vaccines, it is well-described that
immunogenicity of liposomal vaccines can be enhanced (72).
Our data indicate that both AMP and TDB appear to be good
candidate molecules for the M. hyopneumoniae vaccine. The
transcriptomic profile of the Lipo_AMP vaccine was particularly
impressive as it corresponded best to a BTM profile known to
correlate with adaptive immune responses. From all experimental
formulations, Lipo_DDA:TDB induced the highest antibody
and Th1 responses. Unfortunately, this formulation caused a
prolonged ISR after ID administration. Applying this vaccine
only via the IM route could resolve this safety issue, but it would
be probably associated with a loss of immunogenicity (74). In
contrast, the PLGA-based MP formulation did not appear to be
suitable to induce good antibody and Th1 responses, possibly in
part due to a delayed TLR ligand delivery to innate immune cells.
Nevertheless, the fact that this vaccine induced IL17-producing
Th cells at least in some animals is interesting and should be
kept in mind for future investigations. The present work also
identified the SWE_TLR as an interesting vaccine candidate, as
it induced a robust Th1 response and IgA in BAL fluid of one
animal. This vaccine has the advantage of being easy to produce.
Moreover, O/W formulations are known to have a much better
safety profile as W/O vaccines (72). Future studies are required
to address which immunostimulant is best suited for a SWE
adjuvant in the pig. This will require the use of a selection of
identical antigens.
In conclusion, the present study identified promising M.
hyopneumoniae bacterin formulations to be selected for future
challenge experiments, based on their ability to induce strong
innate immune responses and robust Th1 or Th17 responses.
We also demonstrated the utility of transcriptome-based systems
immunology analyses to unravel the mechanistic events leading
to the stimulation of adaptive immune responses after vaccine
injection. While the present study was not designed to identify
the effects of formulation and immunostimulants but rather to
select the most promising candidates from five novel vaccines,
the information provided on these vaccine formulations will also
be very valuable for other vaccines and future adjuvant research.
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